Conference Call to be Held on
May 15, 2023
RANCHO
CORDOVA, Calif., May 10, 2023
/PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a
market leader in automated cell processing tools and services in
the cell and gene therapy field, today announced that the
Company will release its financial results for the first quarter
ended March 31, 2023 and provide a
corporate strategic update on Monday, May
15, 2023, after the close of trading. A conference call and
webcast will follow at 1:30 p.m. PT/
4:30 p.m. ET.
To participate in the conference call, please dial
1-844-889-4331 (domestic), 1-412-380-7406 (international)
or 1-866-605-3852 (Canada). To
access a live webcast of the call, please
visit: https://thermogenesis.com/investors/news-and-events/events-webcasts/.
A webcast replay will be available on ThermoGenesis' website for
three months by visiting the Investor page of the Company's website
at www.thermogenesis.com.
About ThermoGenesis Holdings, Inc.
ThermoGenesis Holdings, Inc. develops, commercializes, and
markets a range of automated technologies for CAR-T and other
cell-based therapies. The Company currently markets a full suite of
solutions for automated clinical biobanking, point-of-care
applications, and automation for immuno-oncology, including its
semi-automated, functionally closed CAR-TXpress™ platform, which
streamlines the manufacturing process for the emerging CAR-T
immunotherapy market. For more information about ThermoGenesis,
please visit: www.thermogenesis.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. The forward-looking statements involve risks and
uncertainties that could cause actual results to differ materially
from the forward-looking statements contained herein. When used in
this press release, the words "anticipate," "believe," "estimate,"
"expect" and similar expressions as they relate to the Company, or
its management are intended to identify such forward-looking
statements. Actual results, performance or achievements could
differ materially from the results expressed in or implied by these
forward-looking statements. Readers should be aware of important
factors that, in some cases, have affected, and in the future could
affect, actual results to differ materially from those expressed in
any forward-looking statements made by or on behalf of the Company.
These factors include without limitation, the ability to obtain
capital and other financing in the amounts and at the times needed
to launch new products and grow our CDMO business, market
acceptance of new products, the nature and timing of regulatory
approvals for both new products and existing products for which the
Company proposes new claims, realization of forecasted revenues,
expenses and income, initiatives by competitors, price pressures,
failure to meet FDA regulated requirements governing the Company's
products and operations (including the potential for product
recalls associated with such regulations), risks associated with
initiating manufacturing for new products, failure to meet Foreign
Corrupt Practice Act regulations, legal proceedings, risks
associated with expanding into the Company's planned CDMO business,
uncertainty associated with the COVID-19 pandemic, and other risk
factors listed from time to time in our reports with the Securities
and Exchange Commission ("SEC"), including, in particular, those
set forth in ThermoGenesis Holdings' Form 10-K for the year ended
December 31, 2022.
Company Contact:
Wendy Samford
916-858-5191
ir@ThermoGenesis.com
Investor Contact:
Paula Schwartz, Rx Communications
917-322-2216
pschwartz@rxir.com
View original
content:https://www.prnewswire.com/news-releases/thermogenesis-holdings-to-announce-financial-results-for-the-first-quarter-ended-march-31-2023-and-provide-a-corporate-strategic-update-301820562.html
SOURCE ThermoGenesis Holdings, Inc.